Trial Profile

A phase III trial comparing subcutaneous and intravenous tocilizumab in patients with rheumatoid arthritis in Japan.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
Indications Rheumatoid arthritis
Focus Registrational; Therapeutic Use
Acronyms MUSASHI
Sponsors Chugai Pharmaceutical

Most Recent Events

27 Aug 2013 Results published in the Arthritis care and research.
14 Nov 2012 12-week outcomes of the extension study presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com